Serum Institute of India Invests in Needle-Free Injection Technology
The Serum Institute of India (SII), a leading vaccine manufacturer, has announced an investment in IntegriMedical, a medical technology company specializing in needle-free injection systems (N-FIS). This collaboration aims to advance N-FIS technology and make it more accessible to patients worldwide.
SII will acquire a 20% stake in IntegriMedical. This investment is expected to accelerate the development and commercialization of N-FIS, offering a more comfortable and painless vaccination experience. N-FIS technology uses a high-velocity jet stream to administer medications, eliminating needle phobia and needle-stick injuries. This aligns with SII's mission of "Health for All" and IntegriMedical's goal to "Transform Healthcare Globally."
"We are constantly seeking opportunities to invest in technologies that make healthcare accessible and affordable," said Adar Poonawalla, CEO of SII. "IntegriMedical's N-FIS represents a significant advancement, potentially revolutionizing vaccine delivery."
"This investment validates the potential of our N-FIS technology," said Sarvesh Mutha, Managing Director of IntegriMedical. "SII's expertise will be invaluable in making our technology available to patients worldwide."
The collaboration leverages SII's manufacturing and distribution strength with IntegriMedical's innovative technology. Together, they aim to improve access to care and healthcare efficiencies.
N-FIS will initially be available in the Indian private market, offering an alternative to traditional injections. The technology promises to eliminate needle phobia, reduce pain, and prevent needle-stick injuries. The global needle-free injection market is expected to reach $27.65 billion by 2028, driven by factors like rising chronic diseases, needle-stick injuries, and advancements in drug delivery technology.